Malcolm McColl
Amministratore Delegato presso Viralytics Ltd.
Posizioni attive di Malcolm McColl
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| Viralytics Ltd. | Amministratore Delegato | 01/01/2013 | - |
ImmVirX Pty Ltd.
 ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Amministratore Delegato | 01/01/2019 | - |
| Presidente | 04/08/2021 | - | |
| Fondatore | 01/01/2019 | - |
Storia della carriera di Malcolm McColl
Precedenti posizioni note di Malcolm McColl
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Mayne Pharma, Inc.
 Mayne Pharma, Inc. Pharmaceuticals: MajorHealth Technology Mayne Pharma, Inc. develops pharmaceutical products. Its services include pharmaceutical development, clinical trial materials, method development and validation, trace metals, stability, and microbiology services. The company was founded in 1994 and is headquartered in Greenville, NC. | Corporate Officer/Principal | 01/01/2007 | 01/01/2010 |
| VIRALYTICS LTD. | Direttore/Membro del Consiglio | 21/01/2013 | - |
| Amministratore Delegato | 21/01/2013 | - | |
| Contatto Relazioni con gli Investitori | - | - | |
| STARPHARMA HOLDINGS LIMITED | Corporate Officer/Principal | 04/01/2011 | - |
Formazione di Malcolm McColl
| Melbourne Business School | Masters Business Admin |
| University of Melbourne | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Australia | 7 |
| Stati Uniti | 2 |
Posizioni
| Chief Executive Officer | 3 |
| Corporate Officer/Principal | 2 |
| Masters Business Admin | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| STARPHARMA HOLDINGS LIMITED | Health Technology |
| Aziende private | 4 |
|---|---|
Mayne Pharma, Inc.
Mayne Pharma, Inc. Pharmaceuticals: MajorHealth Technology Mayne Pharma, Inc. develops pharmaceutical products. Its services include pharmaceutical development, clinical trial materials, method development and validation, trace metals, stability, and microbiology services. The company was founded in 1994 and is headquartered in Greenville, NC. | Health Technology |
Viralytics Pty Ltd.
 Viralytics Pty Ltd. BiotechnologyHealth Technology Viralytics Pty Ltd. engages in the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to infect and kill cancer cells. Its product, CAVATAK, is a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21. The company was founded in 1984 and is headquartered in Sydney, Australia. | Health Technology |
ImmVirX Pty Ltd.
ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Commercial Services |
| Viralytics Ltd. |
- Borsa valori
- Insiders
- Malcolm McColl
- Esperienza
